Menu Search
Equities

Nevro Corp

1N7:FRA

Nevro Corp

Actions
  • Price (EUR)4.00
  • Today's Change-0.540 / -11.89%
  • Shares traded1.00k
  • 1 Year change-71.83%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.

  • Revenue in USD (TTM)419.15m
  • Net income in USD-69.31m
  • Incorporated2006
  • Employees1.22k
  • Location
    Nevro Corp1800 Bridge ParkwayREDWOOD CITY 94065United StatesUSA
  • Phone+1 (650) 251-0005
  • Fax+1 (302) 655-5049
  • Websitehttps://www.nevro.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NVRO:NYQ since
announced		Transaction
value
VYRSA Technologies IncDeal completed30 Nov 202330 Nov 2023Deal completed-73.45%75.00m
Data delayed at least 15 minutes, as of Nov 13 2024 21:10 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.